

New Pneumococcal Vaccine Recommendations

Adults aged ≥ 65 years.

- Adults aged ≥ 65 years who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 (Pevnar 20) or PCV15 (Vaxneuvance)). When PCV15 (Vaxneuvance) is used, it should be followed by a dose of PPSV23 (Pneumovax 23)

Adults aged 19–64 years with certain underlying medical conditions or other risk factors.

- Adults aged 19–64 years with certain underlying medical conditions or other risk factors who have not previously received PCV or whose previous vaccination history is unknown should receive 1 dose of PCV (either PCV20 (Pevnar 20) or PCV15 (Vaxneuvance)). When PCV15 (Vaxneuvance) is used, it should be followed by a dose of PPSV23 (Pneumovax 23).

Dosing schedule

- When PCV15 (Vaxneuvance) is used, the recommended interval between administration of PCV15 (Vaxneuvance) and PPSV23 (Pneumovax 23) is ≥ 1 year.
- A minimum interval of 8 weeks can be considered for adults with an immunocompromising condition, cochlear implant, or cerebrospinal fluid leak to minimize the risk for IPD caused by serotypes unique to PPSV23 (Pneumovax 23) in these vulnerable groups
- **Adults with previous PPSV23 (Pneumovax 23) only.**
 - Adults who have only received PPSV23 (Pneumovax 23) may receive a PCV (either PCV20 (Pevnar 20) or PCV15 (Vaxneuvance)) ≥ 1 year after their last PPSV23 (Pneumovax 23) dose.
 - When PCV15 (Vaxneuvance) is used in those with history of PPSV23 (Pneumovax 23) receipt, it need not be followed by another dose of PPSV23 (Pneumovax 23)
- **Adults with previous PCV13 (Pevnar 13).**
 - The incremental public health benefits of providing PCV15 (Vaxneuvance) or PCV20 (Pevnar 20) to adults who have received PCV13 (Pevnar 13) only or both PCV13 (Pevnar 13) and PPSV23 (Pneumovax 23) have not been evaluated. These adults should complete the previously recommended PPSV23 (Pneumovax 23)
- **Coadministration with other vaccines.**
- PCV15 (Vaxneuvance), PCV20 (Pevnar 20), or PPSV23 (Pneumovax 23) can be coadministered with QIV in an adult immunization program, as concomitant administration (PCV15 (Vaxneuvance) or PPSV23 (Pneumovax 23) and QIV [Fluarix], PCV20 (Pevnar 20) and adjuvanted QIV [Fluad]) has been demonstrated to be immunogenic and safe